JOP20180120A1 - مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 - Google Patents
مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1Info
- Publication number
- JOP20180120A1 JOP20180120A1 JOP/2018/0120A JOP20180120A JOP20180120A1 JO P20180120 A1 JOP20180120 A1 JO P20180120A1 JO P20180120 A JOP20180120 A JO P20180120A JO P20180120 A1 JOP20180120 A1 JO P20180120A1
- Authority
- JO
- Jordan
- Prior art keywords
- dnmt1
- compound
- directed
- iar
- treatment
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 abstract 3
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349227P | 2016-06-13 | 2016-06-13 | |
| US201662393256P | 2016-09-12 | 2016-09-12 | |
| US201662412343P | 2016-10-25 | 2016-10-25 | |
| PCT/IB2017/053511 WO2017216727A1 (en) | 2016-06-13 | 2017-06-13 | Substituted pyridines as inhibitors of dnmt1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20180120A1 true JOP20180120A1 (ar) | 2019-01-30 |
Family
ID=59239935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2018/0120A JOP20180120A1 (ar) | 2016-06-13 | 2018-12-10 | مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10975056B2 (enExample) |
| EP (1) | EP3468953B1 (enExample) |
| JP (1) | JP7051829B2 (enExample) |
| KR (1) | KR20190017030A (enExample) |
| CN (1) | CN109563043B (enExample) |
| AU (1) | AU2017283790B2 (enExample) |
| CA (2) | CA3026226A1 (enExample) |
| CL (1) | CL2018003577A1 (enExample) |
| CO (1) | CO2018013717A2 (enExample) |
| CR (1) | CR20180580A (enExample) |
| DO (1) | DOP2018000273A (enExample) |
| ES (1) | ES2993451T3 (enExample) |
| IL (1) | IL263163B (enExample) |
| JO (1) | JOP20180120A1 (enExample) |
| MA (1) | MA45244A (enExample) |
| MX (1) | MX391600B (enExample) |
| PE (1) | PE20190971A1 (enExample) |
| PH (1) | PH12018502633B1 (enExample) |
| SG (1) | SG11201809559UA (enExample) |
| WO (2) | WO2017216727A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TN2020000158A1 (en) | 2016-10-04 | 2022-04-04 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| RU2020109328A (ru) | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2019195124A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN113480541B (zh) * | 2019-03-07 | 2022-09-02 | 湖南化工研究院有限公司 | 咪唑并吡啶化合物及其中间体的制备方法 |
| WO2022076563A1 (en) * | 2020-10-07 | 2022-04-14 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| PH12023552345A1 (en) * | 2021-03-02 | 2024-04-22 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as dnmt1 inhibitors |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN113278021B (zh) * | 2021-05-29 | 2022-09-23 | 天津全和诚科技有限责任公司 | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 |
| AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| CN114230459A (zh) * | 2021-12-10 | 2022-03-25 | 武汉九州钰民医药科技有限公司 | 一种化合物的制备方法及分析检测方法 |
| WO2023192629A1 (en) * | 2022-04-01 | 2023-10-05 | Herophilus, Inc. | Induction of mecp2 expression by dna methyl transferase inhibitors |
| WO2024156288A1 (en) * | 2023-01-29 | 2024-08-02 | Shanghai Kygent Pharmaceutical Co., Ltd | Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications |
| WO2025006902A2 (en) * | 2023-06-29 | 2025-01-02 | Dana-Farber Cancer Institute, Inc. | Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1) |
| WO2025085756A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| WO2025190285A1 (en) * | 2024-03-12 | 2025-09-18 | Shanghai Kygent Pharmaceutical Co., Ltd | Pyridine compounds, pharmaceutical compositions, and applications |
| CN119306700A (zh) * | 2024-08-28 | 2025-01-14 | 山东大学 | Dnmt1-hdac双靶点抑制剂及其制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030875C (en) | 1990-11-26 | 2002-07-02 | Alan R.P. Paterson | Methods and probes for detecting nucleoside transporter and method for producing the probes |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| ZA942125B (en) | 1993-03-26 | 1994-11-10 | Shell Res Ltd | Herbicidal heterocyclic compounds. |
| CZ203798A3 (cs) | 1995-12-29 | 1998-12-16 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
| AU1295597A (en) | 1995-12-29 | 1997-07-28 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| EP1242366A1 (en) | 1999-12-15 | 2002-09-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease and factor xa inhibitors |
| US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| US20030166554A1 (en) | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| TW200406370A (en) | 2002-06-28 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives |
| TW200406152A (en) | 2002-08-30 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| AR042344A1 (es) | 2002-12-11 | 2005-06-15 | Syngenta Participations Ag | Derivados de 4-(3,3 - dihalo - aliloxi) fenol con propiedades pesticidas |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| CA2520323C (en) | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| WO2004103954A1 (ja) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
| CN1856307A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 喹啉钾通道抑制剂 |
| AU2011253934C1 (en) | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1655296A1 (en) | 2004-10-25 | 2006-05-10 | Graffinity Pharmaceuticals AG | Thrombin inhibitors |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| EP2030971B1 (en) | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| AU2008211729A1 (en) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009034433A2 (en) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| WO2010007756A1 (ja) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ｔｔｋ阻害作用を有するピリジン誘導体 |
| UY32055A (es) | 2008-08-19 | 2010-03-26 | Astrazeneca Ab | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| KR101146010B1 (ko) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물 |
| US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
| KR101790255B1 (ko) | 2009-12-23 | 2017-10-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논 |
| CN102884062B (zh) | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| WO2011103289A2 (en) | 2010-02-17 | 2011-08-25 | Jasco Pharmaceuticals, LLC | Imidazole-2, 4-dione inhibitors of casein kinase 1 |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012040636A2 (en) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| CA2824808A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013019635A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013019621A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP2771012A4 (en) * | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | NEW CONNECTIONS |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| NZ706857A (en) | 2012-09-28 | 2018-05-25 | Ignyta Inc | Azaquinazoline inhibitors of atypical protein kinase c |
| JP2017502968A (ja) | 2014-01-21 | 2017-01-26 | ウォックハート リミテッド | ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用 |
| WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
-
2017
- 2017-06-13 CA CA3026226A patent/CA3026226A1/en not_active Abandoned
- 2017-06-13 MX MX2018015483A patent/MX391600B/es unknown
- 2017-06-13 EP EP17733902.5A patent/EP3468953B1/en active Active
- 2017-06-13 PH PH1/2018/502633A patent/PH12018502633B1/en unknown
- 2017-06-13 MA MA045244A patent/MA45244A/fr unknown
- 2017-06-13 US US16/309,121 patent/US10975056B2/en active Active
- 2017-06-13 SG SG11201809559UA patent/SG11201809559UA/en unknown
- 2017-06-13 AU AU2017283790A patent/AU2017283790B2/en not_active Ceased
- 2017-06-13 CA CA3026211A patent/CA3026211A1/en active Pending
- 2017-06-13 WO PCT/IB2017/053511 patent/WO2017216727A1/en not_active Ceased
- 2017-06-13 WO PCT/IB2017/053509 patent/WO2017216726A1/en not_active Ceased
- 2017-06-13 KR KR1020197000766A patent/KR20190017030A/ko not_active Ceased
- 2017-06-13 CR CR20180580A patent/CR20180580A/es unknown
- 2017-06-13 JP JP2019517187A patent/JP7051829B2/ja active Active
- 2017-06-13 PE PE2018003216A patent/PE20190971A1/es unknown
- 2017-06-13 ES ES17733902T patent/ES2993451T3/es active Active
- 2017-06-13 CN CN201780036908.XA patent/CN109563043B/zh active Active
-
2018
- 2018-11-21 IL IL263163A patent/IL263163B/en unknown
- 2018-12-07 DO DO2018000273A patent/DOP2018000273A/es unknown
- 2018-12-10 JO JOP/2018/0120A patent/JOP20180120A1/ar unknown
- 2018-12-12 CL CL2018003577A patent/CL2018003577A1/es unknown
- 2018-12-18 CO CONC2018/0013717A patent/CO2018013717A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017283790A1 (en) | 2018-11-22 |
| ES2993451T3 (en) | 2024-12-30 |
| BR112018075992A2 (pt) | 2019-04-02 |
| AU2017283790B2 (en) | 2019-08-29 |
| JP2019517596A (ja) | 2019-06-24 |
| US10975056B2 (en) | 2021-04-13 |
| CA3026211A1 (en) | 2017-12-21 |
| PE20190971A1 (es) | 2019-07-09 |
| KR20190017030A (ko) | 2019-02-19 |
| CN109563043A (zh) | 2019-04-02 |
| CA3026226A1 (en) | 2017-12-21 |
| SG11201809559UA (en) | 2018-12-28 |
| IL263163B (en) | 2021-10-31 |
| PH12018502633B1 (en) | 2023-02-01 |
| PH12018502633A1 (en) | 2019-09-30 |
| WO2017216727A1 (en) | 2017-12-21 |
| MA45244A (fr) | 2019-04-17 |
| EP3468953B1 (en) | 2024-05-22 |
| WO2017216726A1 (en) | 2017-12-21 |
| MX391600B (es) | 2025-03-21 |
| CR20180580A (es) | 2019-07-02 |
| EP3468953C0 (en) | 2024-05-22 |
| DOP2018000273A (es) | 2019-03-31 |
| CN109563043B (zh) | 2022-05-31 |
| IL263163A (en) | 2018-12-31 |
| US20190194166A1 (en) | 2019-06-27 |
| CO2018013717A2 (es) | 2019-01-18 |
| MX2018015483A (es) | 2019-03-18 |
| EP3468953A1 (en) | 2019-04-17 |
| CL2018003577A1 (es) | 2019-04-05 |
| JP7051829B2 (ja) | 2022-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180120A1 (ar) | مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MY205300A (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f] isoquinoline derivatives useful in the treatment of cancer | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| NZ748946A (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| NZ715747A (en) | Syk inhibitors | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| IN2015MN00002A (enExample) | ||
| NZ726366A (en) | Syk inhibitors | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| HK1231390A1 (zh) | 用於局部给药的药用组合物 | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| HK1201839A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands | |
| MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
| HK1202116A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands | |
| WO2014106826A3 (en) | Anthracycline analogue and uses thereof | |
| EA201990023A1 (ru) | Замещенные пиридины в качестве ингибиторов dnmt1 | |
| WO2017085733A3 (en) | Analgesic lipoic acid derivatives and the preparation thereof |